General MedicationsORALStandard

SUMATRIPTAN SUCCINATE

Standard Dose

EQ 50MG BASE

Max Dose

Refer to approved labeling

Primary Use

Review priority: UNKNOWN Marketing status: Prescription

Summary

Approval overview SUMATRIPTAN SUCCINATE is listed in Drugs@FDA under application 219036 (ANDA).

Review priority: UNKNOWN Marketing status: Prescription Active ingredient SUMATRIPTAN SUCCINATE Form and strength TABLET;ORAL - EQ 50MG BASE Sponsor VKT PHARMA Submission history Latest submission status date: 2025-03-28 00:00:00.

Structured Monograph

Clinical summary

Approval overview SUMATRIPTAN SUCCINATE is listed in Drugs@FDA under application 219036 (ANDA). Review priority: UNKNOWN Marketing status: Prescription Active ingredient SUMATRIPTAN SUCCINATE Form and strength TABLET;ORAL - EQ 50MG BASE Sponsor VKT PHARMA Submission history Latest submission status date: 2025-03-28 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Prescription
• Review priority: UNKNOWN

Interaction Notes

No interaction notes stored yet.